Enrichment of Cells

• US 20100260721A1
• Filed: 01/17/2007
• Published: 10/14/2010
• Est. Priority Date: 01/18/2006
• Status: Abandoned Application

• Current Assignee: University of Leeds
• Original Assignee: University of Leeds
• Inventors: Emery, Paul, English, Anne, Jones, Elena, McGonagie, Dennis
• Application Number:
  US12/223,056
• Publication Number:
  US 20100260721A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/0668 Mesenchymal stem cells from other natural sources

Abstract

The present invention relates to methods of isolating and enriching mesenchymal stem cells (MSCs) comprising treating a tissue sample comprising cells and extracellular matrix with an amount of a collagenase that is sufficient to free MSCs from the extracellular matrix in a liquid medium and then isolating a fraction of the medium containing MSCs. The isolated MSCs can be isolated in surprisingly large numbers such that the fraction can have immediate use in a number of clinical contexts. This represents an advance of prior art techniques that either require the pooling of large volumes of sample tissues from different sources or require MSCs to be expanded in culture. The invention therefore further concerns the clinical use of cells isolated according to the methods of the first aspect of the invention.

Claims

1. A method of isolating and enriching mesenchymal stem cells (MSCs) comprising:

(a) treating a tissue sample comprising cells and extracellular matrix with an amount of a collagenase that is sufficient to free MSCs from the extracellular matrix in a liquid medium; and

(b) isolating a fraction of the medium containing MSCs.

2. The method according to claim 1 wherein the tissue sample is from bone marrow.

3. The method according to claim 2 wherein the sample is a punch biopsy from the pelvis, sternum or femur.

4. The method according to claim 1, wherein the tissue sample comprises the floating fat fraction (FFF).

5. The method according to claim 1, wherein the tissue sample is from a tissue selected from the group comprising a bone aspirate, synovium and fat pads.

6. The method according to claim 1, wherein the sample is placed in buffer comprising 0.25% collagenase.

7. The method according to claim 1, wherein the sample is treated with collagenase for 3-4 hours.

8. The method according to claim 1, wherein the fraction containing MSCs is obtained by removing any solids and centrifuging the liquid medium to isolate a fraction comprising single cells.

9. The method according to claim 1, wherein step (a) comprises two separate collagenase digestions.

10. The method according to claim 1, wherein step (a) further comprises a hyaluronidase digestion.

11. The method according to claim 9, wherein the tissue sample is bone and the MSCs are for use in bone repair.

12. The method according to claim 1, wherein step (b) further comprises a further enrichment step.

13. The method according to claim 12 wherein the further enrichment step utilizes magnetic beads.

14. The method according to claim 12 wherein the further enrichment step involves FACS sorting.

15. The method according to claim 12, wherein the further enrichment step is based on isolating MSCs with a phenotype characterized by one of the markers identified in Table 1

16. The method according to claim 15 wherein the phenotype is CD45^lowLNGFR⁺, CD45^lowD7-FIB⁺LNGFR⁺ or CD45^lowD7-FIB⁺.

17. Isolated mesenchymal stem cells (MSC) enriched according to the method of claim 1.

18. Isolated mesenchymal stem cells (MSC) according to claim 17 for use as a medicament.

19. A medicament according to claim 18 for use in cell therapy.

20. The medicament according to claim 18 wherein the MSC is genetically manipulated for use in gene therapy.

21. A kit for enriching mesenchymal stem cells (MSC) comprising a collagenase.

22. A method of performing cell therapy on a subject in need of such therapy comprising:

(a) obtaining a tissue sample comprising MSCs and extracellular matrix from said subject;

(b) treating said tissue sample with an amount of a collagenase that is sufficient to free MSCs from the extracellular matrix in a liquid medium;

(c) isolating a fraction of the medium containing MSCs; and

(d) re-introducing said fraction into said subject at a body site that permits said subject to benefit from said cell therapy.

24. The method according to claim 22 comprising the further step of genetically manipulating the MSC.

25. The method according to claim 22, wherein the cell therapy is for the purpose of clinically managing conditions selected from the group comprising:

bone repair, cartilage repair, skeletal muscle repair, tendon repair, ligament repair, meniscus repair, cardiac muscle repair, spinal cord injury, Parkinson'"'"'s diseases and other neurodegenerative diseases, immune-mediated tissue rejection, graft-versus-host disease, rheumatoid arthritis, regeneration of fatty material, vascular repair or ischaemic vascular lesions or osteoporosis.

26. The method according to claim 22 for repairing bone.

27. The method according to claim 22 for repairing cartilage.

28. The method according to claim 22 for treating osteoarthritis.

29. The method according to claim 22 for treating osteoporosis.

23. A method of performing cell therapy on a subject in need of such therapy comprising:

(a) obtaining a tissue sample comprising MSCs and extracellular matrix from a cadaver or donor;

(b) treating said tissue sample with an amount of a collagenase that is sufficient to free MSCs from the extracellular matrix in a liquid medium;

(c) isolating a fraction of the medium containing MSCs; and

(d) introducing said fraction into said subject at a body site that permits said subject to benefit from said cell therapy.

30. (canceled)